Novavax Inc.’s (NASDAQ: NVAX) shares soared 50% in morning hours on Friday after the company announced that its COVID-19 vaccine candidate displayed
Categories
Biotechnology
Fate Therapeutics (FATE) looks headed for a turnaround post-COVID
Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharma company, has been drawing the market's attention after reporting positive results from advanced-stage clinical
Codexis (CDXS) may be moving closer to profitability, after beating slowdown
Biosciences company Codexis, Inc. (NASDAQ: CDXS) has emerged stronger from a rough patch, supported mainly by the resilience of its partners to
Covid vaccine won’t dent Ampio Pharma’s market: CEO Michael Macaluso
Since its foundation in 2008, Ampio Pharmaceuticals (NYSE: AMPE) has been focused on delivering a drug that treats inflammation caused by a
Moderna (MRNA): Development programs, additional approvals provide optimism
Moderna Inc. (NASDAQ: MRNA) seems to be on a roll right now. The stock has skyrocketed over 500% in the past one
Moderna’s (MRNA) stock gains on COVID-19 vaccine approval from the European Commission
Shares of Moderna Inc. (NASDAQ: MRNA) gained 6.3% in afternoon hours on Wednesday as the company received approval from the European Commission
Eli Lilly (LLY) is paving the way to a strong 2021
Shares of Eli Lilly & Co. (NYSE: LLY) were up over 2% on Wednesday. The stock has gained over 30% since the
Veru Inc. (VERU) Q4 2020 Earnings Call Transcript
Veru Inc. (NASDAQ: VERU) Q4 2020 earnings call dated Dec. 09, 2020. Corporate Participants: Samuel Fisch -- Director, Investor Relations Mitchell Steiner -- Chairman, President, and
Avid Bioservices, Inc. (CDMO) Q2 2021 Earnings Call Transcript
Avid Bioservices, Inc. (NASDAQ: CDMO) Q2 2021 earnings call dated Dec. 02, 2020 Corporate Participants: Tim Brons -- Investor Relations Nicholas Green -- President and Chief
Is it time to book profits from Moderna?
Moderna (NASDAQ: MRNA) stock has soared a staggering 679% since the beginning of this year. If you did identify the potential of
Alexion’s long-term prospects remain intact amid continued focus on rare diseases
Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) has stood out in the crowded pharmaceuticals marketplace by developing effective treatments for certain rare health conditions. The
China Biologic Products Holdings, Inc. (CBPO) Q3 2020 Earnings Call Transcript
China Biologic Products Holdings, Inc. (NASDAQ: CBPO) Q3 2020 earnings call dated Nov. 25, 2020. Corporate Participants: Philip Lisio -- Investor Relations, The Foote
Is it the right time to invest in Agilent Technologies (A)?
Agilent Technologies, Inc. (NYSE: A) ended fiscal 2020 on a positive note, bettering its performance consistently after experiencing a slowdown in the
Palatin Technologies, Inc. (PTN) Q1 2021 Earnings Call Transcript
Palatin Technologies, Inc. (AMEX: PTN) Q1 2021 earnings call dated Nov. 17, 2020 Corporate Participants: Carl Spana -- President and Chief Executive Officer Stephen
COVID-19 vaccine: Pfizer (PFE) and Moderna (MRNA) are ahead in the race, where are the others?
Pfizer Inc. (NYSE: PFE) and Moderna Inc. (NASDAQ: MRNA) have made significant progress in their efforts to develop a vaccine against the
Moderna (MRNA) gains as COVID-19 vaccine candidate shows over 94% efficacy
Shares of Moderna Inc. (NASDAQ: MRNA) were up over 8% in morning trade on Monday as the company reported positive results from
Bio-Path Holdings, Inc. (BPTH) Q3 2020 Earnings Call Transcript
Bio-Path Holdings, Inc. (NASDAQ: BPTH) Q3 2020 earnings call dated Nov. 13, 2020 Corporate Participants: Will O'Connor -- Stern Investor Relations Peter Nielsen -- President, Chief
Biocept Inc (BIOC) Q3 2020 Earnings Call
Biocept Inc (NASDAQ: BIOC) Q3 2020 earnings call dated Nov. 12, 2020 Corporate Participants: Bruce Voss -- Investor Relations Michael W. Nall -- President and Chief
PDL BioPharma, Inc. (PDLI) Q3 2020 Earnings Call Transcript
PDL BioPharma, Inc. (NASDAQ: PDLI) Q3 2020 earnings call dated Nov. 11, 2020 Corporate Participants: Jody Cain -- Senior Vice President, LHA Dominique Monnet -- President
Biogen (BIIB) might need to revisit pipeline after Alzheimer’s drug setback
The controversy surrounding biotechnology firm Biogen's (NASDAQ: BIIB) Alzheimer's drug Aducanumab took a positive turn last week after the FDA issued a
Immunogen Inc (IMGN) Q3 2020 Earnings Call Transcript
Immunogen Inc (NASDAQ: IMGN) Q3 2020 earnings call dated Nov. 06, 2020 Corporate Participants: Courtney O'Konek -- Senior Director of Corporate Communications and Investor